Pfizer Inc. declared a novel antibiotic, Zavicefta, which is a new combination antibiotic meant exclusively to treat patients with doubtful or confirmed aerobic Gram-negative bacterial infections that are cause by resistant bacteria needing hospitalization. This drug is now available in Germany as well as U.K.
Gram-negative bacteria can lead to several types of infections such as plague, cholera, sexually transmitted diseases like gonorrhea, and respiratory infections such as pneumonia. These bacteria are spread to human body in various ways like water, food, in contact with infected animals, or insect bites.
Zavicefta is a defined amalgamation of ceftazidime which is an antibiotic that belongs to class of third generation cephalosporins long approved in the EU and avibactam, i.e., a new beta-lastamase inhibitor.
Pfizer says that the drug has been formulated to alter and managing of hard-to-treat infections which are more and more getting resistant to present care standards, and constitutes a vital advance treatment, particularly in patients in whom the result of antibiotic treatment failure owing to resistance could be withering.
Especially in Gram-negative bacteria, the amount of resistance to cephalosporins and many other antibiotics is escalating; by suppressing the beta-lactamases action, that portray a significant role in the growth of bacterial resistance to such antibiotics. Avibactam reinstates the ceftazidime activity.
Dr Matthew Dryden, consultant microbiologist at NHS Hampshire Hospitals says that, “The need to tackle multi-drug resistant pathogens is pressing and will require a lot of ingenuity. In hospital and in the community, it is becoming increasingly difficult to predict Gram-negative sensitivity to antibiotics.”
He further added that the rate of carbapenem-resistant Enterobacteriacae is estimated to rise substantially in hospitals in UK, similar to the way it has done everywhere else in the coming 10 to 15 years.
This is “particularly troubling as carbapenems are one of the remaining drugs used as a last line of defence. There is an urgent need for new diagnostics, antibiotics and therapeutic strategies that address the challenge of treating hospitalised patients with infections caused by resistant pathogens, for which very few effective and tolerable treatment options are currently available.”
The research clinical trials have displayed Zavicefta to be very efficient to present carbapenem standards of care in treating severe aerobic Gram-negative infections which even include patients suffering from infections occurred due to ceftazidime-resistant bacteria.
In June 2016, in European Union, Zavicefta was conjointly produced by Allergan and AstraZeneca. Of which, AZ was accountable for global commercialization rights excluding North America, since that belongs to Allergan, but channeled them to Pfizer along with sales of huge parts of its small molecule antibiotics business in August.